R-MBDB

R-MBDB is the R-enantiomer of N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB), a small molecule entactogen of the phenethylamine class and the alpha-ethyl homologue of MDMA. It functions primarily as a serotonin-norepinephrine releasing agent (SNRA), exhibiting high selectivity for the serotonin transporter (SERT) and norepinephrine transporter (NET) over the dopamine transporter (DAT). Originally synthesized by David E. Nichols in 1986, the compound is being evaluated by PharmAla Biotech for potential clinical applications, most notably in the treatment of autism spectrum disorder. R-MBDB is distinguished from MDMA by its reported lack of hallucinogenic properties and potentially lower neurotoxic profile.

Other names

(R)-MBDBS-MBDBEdenMethyl-J(R)-N-methyl-1-(1,3-benzodioxol-5-yl)butan-2-amine